Esperion Therapeutics Completes $33 Million Preferred Financing to Advance Its Novel Oral LDL-C Lowering Therapy to Later Stage

  Esperion Therapeutics Completes $33 Million Preferred Financing to Advance
  Its Novel Oral LDL-C Lowering Therapy to Later Stage Clinical Trials

Business Wire

ANN ARBOR, Mich. -- April 25, 2013

Esperion Therapeutics, Inc., a clinical stage biopharmaceutical company
focused on developing and commercializing first-in-class, oral low-density
lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of
hypercholesterolemia and other cardiometabolic disorders, today announced that
it has completed a $33 million preferred stock financing led by new investor
Longitude Capital. Existing investors Aisling Capital, Alta Partners, Domain
Associates, Arboretum Ventures and Asset Management also participated in the
financing. In connection with this financing, Longitude’s Patrick Enright will
join Esperion’s board of directors.

“This financing allows us to continue to advance our novel lead product
candidate, ETC-1002, for which we have 100 percent worldwide rights, in
multiple ongoing and planned Phase 2 clinical trials,” said Tim Mayleben,
Esperion’s president and chief executive officer.

About ETC-1002 and Statin Intolerance

ETC-1002 is a first-in-class, orally available, once-daily LDL-C lowering
small molecule therapy designed to target known lipid and carbohydrate
metabolic pathways to lower levels of LDL-C and to avoid many of the side
effects associated with existing LDL-C lowering medications.  Phase 2a
clinical trials of ETC-1002 conducted so far have demonstrated significant
average LDL-C reductions as high as 43% and reductions comparable to statins
in levels of high sensitivity C-reactive protein, or hsCRP, a key marker of
inflammation associated with cardiovascular disease.

ETC-1002 has been well tolerated and not associated with serious side effects,
and there have been no serious adverse events in over 230 ETC-1002 treated
patients. Unlike some therapies currently in development that, if approved,
will require regular injections, ETC-1002 is an oral pill taken once daily,
the same way traditional LDL-C lowering therapies have been administered.

It is estimated that more than two million U.S. adults have discontinued
statin therapy because of muscle pain or weakness. Because symptoms of muscle
pain or weakness occur in up to 20 percent of patients on statin therapy in
clinical practice, Esperion believes the size of the statin-intolerant market
is poised to grow if a novel non-statin therapy becomes available.

“I am very pleased to become involved with Esperion,” added Patrick Enright of
Longitude. “I look forward to working with Roger, Tim and the entire Esperion
team to realize the full potential of ETC-1002 in patients with elevated LDL-C
who cannot tolerate statin therapy.”

“To date, we have used our resources efficiently to get us to this critical
stage of development with what I believe is an LDL-C lowering therapy with
differentiated non-statin mechanisms,” added Roger Newton, Ph.D., Esperion’s
executive chairman and chief scientific officer. “We intend to use this
financing to advance ETC-1002 through the next important phase of
development.”

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a biopharmaceutical company focused on the
research, development and commercialization of therapies for the treatment of
patients with elevated levels of low-density lipoprotein cholesterol (LDL-C)
and other cardiometabolic risk factors. ETC-1002, Esperion’s lead product
candidate, is a novel, first-in-class, orally available, once-daily LDL-C
lowering small molecule therapy designed to target known lipid and
carbohydrate metabolic pathways to lower levels of LDL-C and to avoid many of
the side effects associated with existing LDL-C lowering therapies. ETC-1002
is targeted for statin-intolerant patients with elevated levels of LDL-C. For
more information, please visit www.esperion.com.

About Aisling Capital

Aisling Capital, a leading private equity firm headquartered in New York with
$1 billion under management, invests in products, technologies and businesses
that advance health. In addition to investing in companies developing
pharmaceutical, biopharmaceutical and medical products, Aisling invests in
businesses that provide drug development, manufacturing and other important
services to the healthcare industry. For more information, please visit
www.aislingcapital.com.

About Alta Partners

Alta Partners is a San Francisco-based venture capital firm focused on life
sciences investing. Founded in 1996, the firm has raised over $2 billion in
committed capital through eight venture fund programs. Alta invests in
biopharmaceutical and medical technology companies across the development
continuum, from company formation to later-stage opportunities, and has funded
more than 130 life sciences companies to date. For more information, please
visit www.altapartners.com.

About Arboretum Ventures

Arboretum Ventures is an early-stage venture capital firm specializing in the
healthcare sector. Arboretum invests throughout the United States, with a
special interest in the Midwest region. Founded in 2002 and headquartered in
Ann Arbor, MI, Arboretum currently manages $240 million in capital. For more
information, please visit www.arboretumvc.com.

About Asset Management

Asset Management was founded in 1965 by Franklin "Pitch" Johnson, formerly of
Draper and Johnson. Over nearly half a century, the firm has provided
early-stage financing for groundbreaking companies such as Amgen, Tandem
Computer and Applied BioSystems. Today, the firm continues its diversified
investing approach by deploying capital in early-stage companies focused on
therapeutics, digital health, big data analytics and mobility. The firm is run
by a leadership team comprised of former operators with expertise in science,
engineering and medicine. For more information, please visit www.assetman.com.

About Domain Associates

Domain Associates, L.L.C. is a venture capital firm founded in 1985 with an
exclusive focus on life sciences. With $2 billion of capital under management,
Domain is headquartered in Princeton, NJ with a second office in San Diego,
CA. For more information, please visit www.domainvc.com.

About Longitude Capital

Longitude Capital, an investment firm with over $700 million in assets under
management, focuses on venture growth investments in the life sciences
industry. The firm targets investment opportunities in privately held
biotechnology and medical device companies that are clinically de-risked and
have well-defined capital requirements. Longitude also actively invests in
PIPEs and structured transactions in publicly traded companies. Longitude has
offices in Menlo Park, CA and Greenwich, CT. For more information, please
visit www.longitudecapital.com.

Contact:

BrewLife
Denise Powell
510-703-9491
dpowell@brewlife.com